FDA
-
-
-
-
-
-
-
MBX Biosciences reports sustained one-year data for weekly drug trial
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on MBX Biosciences Inc (MBX): "operating flexibility to reach multiple value-creating events this year"
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on MBX Biosciences Inc (MBX)
-
-
-
-
-
-
-
Microbix Launches New Products to Support H3N2 Flu Testing
-
-
-
-
-
-
-
Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates
-
-
-
-
-
-
-
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
-
-
-
-
-
-
-
Microbix & Bulgaria’s NCIPD Execute Supply Agreement
-
330,532 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

